Research/Areas of Interest: Our research interest is in understanding the genetic basis of cardiovascular disease, with a focus on how regulation of gene expression affects cardiovascular disease phenotypes, with a goal to develop therapeutic agents that can ameliorate pathological phenotypes and thus provide treatments for cardiovascular diseases. The activities of the Chin Lab include developing an enzyme replacement therapy for a genetic cardiomyopathy disorder, Barth Syndrome, and identifying molecular pathways that regulate the pathogenesis of hypertrophic cardiomyopathy, in both human tissue and mouse models. His lab has expertise in expression and purification of proteins, in transcriptomics, proteomics, metabolomics and spatial transcriptomics. His lab also has expertise in analyzing developmental phenotypes in genetically modified mice, differentiating embryonic stem cells to cardiomyocytes, culturing primary vascular, cardiac and embryonic cells for gain and loss of function studies and also in assessing for cardiac hypertrophy and heart failure in vitro and in vivo, as well as experience in measuring mitochondrial respiration, skeletal muscle contraction and mouse treadmill exercise performance.


  • MD, University of Rochester, United States, 1991
  • PhD, University of Rochester, United States, 1989
  • MS, University of Rochester, United States, 1988
  • AB, Princeton University, United States, 1983